Tags

Type your tag names separated by a space and hit enter

Coronavirus Disease 2019 Vaccine Development: An Overview.
Viral Immunol. 2021 04; 34(3):134-144.VI

Abstract

To this day, the coronavirus disease 2019 (COVID-19) pandemic has not shown signs of abating. Moreover, the virus responsible for the pandemic, severe acute respiratory syndrome coronavirus 2, has evolved into three different variants. This phenomenon highlights an even greater need to develop drugs and vaccines to control the rate of infection and spread of the disease. As of July 7, 2020, at least 160 vaccine candidates, 21 of which have entered the clinical trial phase, have been developed. This article describes the latest advances in development, reliable platforms, strategies used, and challenges that remain in developing COVID-19 vaccines.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Sumirtanurdin R
Pharmacist Profession Education, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia. Biotechnology Pharmacy Laboratory, Department of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.
Barliana MI
Biotechnology Pharmacy Laboratory, Department of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia. Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia.

MeSH

COVID-19COVID-19 VaccinesDrug DevelopmentGenetic VectorsHumansSARS-CoV-2Spike Glycoprotein, CoronavirusT-LymphocytesVaccines, DNAVaccines, SyntheticVirus Replication

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32985963

Citation

Sumirtanurdin, Riyadi, and Melisa Intan Barliana. "Coronavirus Disease 2019 Vaccine Development: an Overview." Viral Immunology, vol. 34, no. 3, 2021, pp. 134-144.
Sumirtanurdin R, Barliana MI. Coronavirus Disease 2019 Vaccine Development: An Overview. Viral Immunol. 2021;34(3):134-144.
Sumirtanurdin, R., & Barliana, M. I. (2021). Coronavirus Disease 2019 Vaccine Development: An Overview. Viral Immunology, 34(3), 134-144. https://doi.org/10.1089/vim.2020.0119
Sumirtanurdin R, Barliana MI. Coronavirus Disease 2019 Vaccine Development: an Overview. Viral Immunol. 2021;34(3):134-144. PubMed PMID: 32985963.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coronavirus Disease 2019 Vaccine Development: An Overview. AU - Sumirtanurdin,Riyadi, AU - Barliana,Melisa Intan, Y1 - 2020/09/23/ PY - 2020/9/29/pubmed PY - 2021/5/7/medline PY - 2020/9/28/entrez KW - SARS-CoV-2 KW - challenges KW - platforms KW - progress SP - 134 EP - 144 JF - Viral immunology JO - Viral Immunol VL - 34 IS - 3 N2 - To this day, the coronavirus disease 2019 (COVID-19) pandemic has not shown signs of abating. Moreover, the virus responsible for the pandemic, severe acute respiratory syndrome coronavirus 2, has evolved into three different variants. This phenomenon highlights an even greater need to develop drugs and vaccines to control the rate of infection and spread of the disease. As of July 7, 2020, at least 160 vaccine candidates, 21 of which have entered the clinical trial phase, have been developed. This article describes the latest advances in development, reliable platforms, strategies used, and challenges that remain in developing COVID-19 vaccines. SN - 1557-8976 UR - https://www.unboundmedicine.com/medline/citation/32985963/Coronavirus_Disease_2019_Vaccine_Development:_An_Overview_ DB - PRIME DP - Unbound Medicine ER -